Please assess the completion status of the following clinical trial:

Trial Title: Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Prior history of relapsing remitting MS~* SPMS defined as progressive increase of disability over at least 6 months~* EDSS score of 3.0 to 6.5~* No relapse of corticosteroid treatment within 3 months~Exclusion Criteria:~* Women of child bearing potential must use reliable forms of contraception.~* Diagnosis of Macular edema during screening period~* Any medically unstable condition determined by investigator.~* Unable to undergo MRI scans~* Hypersensitivity to any study drugs or drugs of similar class

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Siponimod (BAF312) (Type: EXPERIMENTAL): Participants started on Day 1 and were uptitrated from 0.25 mg to 2 mg of BAF312 orally over a period of 6 days. After Day 7, participants continued on the treatment epoch for 3 months. During the Core Part of the study, participants participated in a maximum of 3 epochs. Following the Core Part, eligible patients enter the Extension Part during which all receive open-label BAF312.
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo to BAF312 was administered orally during the Core Part of the trial. Following the Core Part, eligible participants enter the Extension Part during which all receive open-label BAF312.

Based on this trial design, predict the completion outcome and termination type (if applicable).